Skip to search formSkip to main contentSkip to account menu

Taxoprexin

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

docosahexaenoyl-paclitaxel

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Cell-targeted cytotoxics: a new generation of cytotoxic agents for cancer treatment
The therapeutic arsenal for the treatment of cancers has been considerably revised over the past 15 years, with the continuous… 
2009
2009
Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin®, in resistant solid tumor malignancies
PurposeTo determine the maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics of weekly docosahexaenoic acid… 
2008
2008
Phase II open-label study of weekly taxoprexin (TXP) as first-line treatment in patients with metastatic cutaneous and mucosal malignant melanoma
9056 Background: Taxoprexin (TXP) is a covalent conjugate of paclitaxel and the fatty acid docosahexanoic acid. Due to its unique… 
2004
2004
Phase II study of DHA-paclitaxel (TXP) as first line chemotherapy in patients with hormone refractory prostate cancer (HRPC)
4657 Background: DHA-paclitaxel (Taxoprexin) is a covalent conjugate of paclitaxel and docosahexaenoic acid that has greater… 
2004
2004
Phase II study of DHA-paclitaxel (TXP) as first line chemotherapy in patients with hormone refractory prostate cancer (HRPC).
4657 Background: DHA-paclitaxel (Taxoprexin) is a covalent conjugate of paclitaxel and docosahexaenoic acid that has greater… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)